BioAtla, Inc. BCAB
Set alert
2.07 USD -0.03 -1.43%
As of Nov 2, 3:50 PM ET
2.06 Day range 2.11
1.07 52-week range 71.50
- YTD
- -92.71%
- 1 year
- -94.08%
- Open
- 2.11
- Prev close
- 2.10
- Mkt cap
- 3.45M
- Vol
- 310
- Avg vol
- 54.30K
- EPS
- -25.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.06
- High
- 2.11
- Forward P/E
- -0.42
- Beta
- 1.02
- Short ratio
- 3.70
- Inst. own
- 42.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.72
- 200-d avg
- 1.99
- 1y target
- 9.00
Analyst view
Consensus: none
Price target (mean) 9.00 +334.8% upside
Now 2.07
- Target (low)
- 5.00
- Target (mean)
- 9.00
- Target (high)
- 13.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 4
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.34 | -0.34 – -0.33 | -0.56 | +39.3% | 0 | 0.0% | 3 |
| Next quarter | -0.39 | -0.39 – -0.39 | -0.48 | +18.8% | 0 | 0.0% | 1 |
| Current year | -1.48 | -1.48 – -1.46 | -2.58 | +42.6% | 11.00M | 0.0% | 3 |
| Next year | -1.31 | -1.51 – -1.02 | -1.48 | +11.5% | 0 | -100.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Sep 16, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| May 23, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| May 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 28, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Mar 27, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 5, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 8, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 25, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 2, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 2, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Aug 2, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2023 | JMP Securities | Reiterated | Outperform | Outperform |
| May 15, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 12, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Apr 17, 2023 | EF Hutton | Maintained | — | Buy |
| Apr 3, 2023 | JP Morgan | Maintained | — | Overweight |
| Mar 28, 2023 | BTIG | Maintained | — | Buy |
| Mar 27, 2023 | JMP Securities | Maintained | — | Outperform |
| Mar 24, 2023 | Credit Suisse | Reiterated | — | Neutral |
| Mar 24, 2023 | EF Hutton | Reiterated | — | Buy |
| Mar 24, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 5, 2023 | EF Hutton | Initiated | — | Buy |
| Nov 4, 2022 | Credit Suisse | Maintained | — | Neutral |
| Sep 15, 2022 | JMP Securities | Initiated | — | Market Outperform |
| Aug 10, 2022 | Credit Suisse | Maintained | — | Neutral |
| Aug 10, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 5, 2022 | Credit Suisse | Downgrade | Outperform | Neutral |
| Mar 21, 2022 | HC Wainwright & Co. | Initiated | — | Buy |